SCHEMBL1642011

SCHEMBL1642011

O=C(O)CNC(=O)c1c(O)c(C(=O)NCc2ccncc2)cn(Cc2ccccc2)c1=O

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 3/20 0.88
EGLN1 Q9GZT9 8/20 0.52
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
USP2 O75604 3/20 0.48
MAPT P10636 3/20 0.48
TSHR P16473 3/20 0.48
ALDH1A1 P00352 4/20 0.46
HPGD P15428 4/20 0.46
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
TRPA1 O75762 1/20 0.46
HTT P42858 2/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640295 0.94 EGLN3 (1.00) EGLN3EGLN1LMNASMN1; SMN2MAPT
SCHEMBL1642598 0.89 EGLN3 (0.90) EGLN3EGLN1LMNAMAPTALDH1A1
SCHEMBL12727509 0.88 EGLN3 (0.68) EGLN3EGLN1
SCHEMBL1642474 0.86 EGLN3 (0.78) EGLN3EGLN1LMNASMN1; SMN2USP2
SCHEMBL1642745 0.85 EGLN3 (0.83) EGLN3EGLN1LMNASMN1; SMN2MAPT
SCHEMBL1640593 0.85 EGLN3 (0.83) EGLN3EGLN1
SCHEMBL1641775 0.84 EGLN3 (0.81) EGLN3EGLN1LMNASMN1; SMN2MAPT
SCHEMBL1641933 0.84 EGLN3 (0.81) EGLN3EGLN1LMNAMAPTALDH1A1
SCHEMBL1640549 0.82 EGLN3 (0.78) EGLN3EGLN1LMNAKDM4EHTT
SCHEMBL1642321 0.82 EGLN3 (0.78) EGLN3EGLN1SMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN3 3/4885EGLN1 6/4885LMNA 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.